Xeris Pharmaceuticals Inc Stock: price and insider trades · United States

Xeris Biopharma Holdings, Inc. (ticker: XERS) is a U.S.-listed biopharmaceutical company trading on the Nasdaq, with headquarters in Chicago, Illinois, United States. For French-speaking investors, Xeris is best understood as a specialty pharma player focused on ready-to-use drug formulations designed to simplify administration, improve usability for patients and caregivers, and reduce some of the practical burdens associated with traditional injectable therapies. The company was originally founded as Xeris Pharmaceuticals, Inc., and its long-term strategy has been built around proprietary formulation platforms, notably XeriSol and XeriJect, which underpin both marketed products and pipeline development programs.

Xeris’ business model centers on differentiated specialty pharmaceuticals rather than a broad, diversified large-cap portfolio. The company’s commercial base is currently anchored by three marketed products. Gvoke is a ready-to-use liquid glucagon for severe hypoglycemia. Keveyis is a proven therapy for primary periodic paralysis. Recorlev is used in endogenous Cushing’s syndrome and has been the main growth driver in recent reporting periods. This three-product structure gives the company a more balanced revenue base than a single-asset story, while still leaving meaningful concentration in a small number of specialty indications.